Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls.

Humans Male Neoplasm Staging Testicular Neoplasms / pathology Neoplasms, Germ Cell and Embryonal Life Expectancy

Future life expectancy Germ-cell tumors SEER program Testis cancer

Journal

International urology and nephrology

ISSN: 1573-2584

Titre abrégé: Int Urol Nephrol

Pays: Netherlands

ID NLM: 0262521

Informations de publication

Date de publication:
Dec 2023

Historique:

received: 19 06 2023

accepted: 20 08 2023

medline: 30 10 2023

pubmed: 29 8 2023

entrez: 28 8 2023

Statut: ppublish

Résumé

It is unknown whether five-year overall survival (OS) differs and to what extent between testicular germ-cell tumor (TGCT) patients and age-matched male population-based controls. We identified newly diagnosed (2004-2014) TGCT patients within Surveillance Epidemiology and End Results database 2004-2019. We compared OS between non-seminoma (NS-TGCT) and seminoma (S-TGCT) patients relative to age-matched male population-based controls based on Social Security Administration Life-Tables. Smoothed cumulative incidence plots displayed cancer-specific mortality (CSM) vs. other-cause mortality (OCM). Of all 20,935 TGCT patients, 43% had NS-TGCT and 57% had S-TGCT. Of NS-TGCT patients, 63% were stage I vs. 16% stage II vs. 21% stage III. Of S-TGCT patients, 86% were stage I vs. 8% were stage II vs. 6% stage III. Five-year OS differences between NS-TGCT patients vs age-matched male population-based controls were 97 vs. 99% (Δ = 2%) for stage I, 96 vs. 99% (Δ = 3%) for stage II, 76 vs 98% (Δ = 22%) for stage III. Five-year OS differences between S-TGCT patients vs age-matched male population-based controls were 97 vs. 98% (Δ = 1%) for stage I, 95 vs. 97% (Δ = 2%) for stage II, 87 vs. 98% (Δ = 11%) for stage III. OCM rates ranged from 1 to 3% in NS-TGCT patients and from 2 to 4% in S-TGCT patients. The OS difference between NS-TGCT patients vs. age-matched male population-based controls was invariably higher across all stages (2-22%) than for S-TGCT patients (1-11%). Reassuringly, OCM rates were marginal in stage I and stage II patients. Conversely, higher OCM rates were recorded in stage III patients.

Sections du résumé

BACKGROUND BACKGROUND

It is unknown whether five-year overall survival (OS) differs and to what extent between testicular germ-cell tumor (TGCT) patients and age-matched male population-based controls.

MATERIALS METHODS

We identified newly diagnosed (2004-2014) TGCT patients within Surveillance Epidemiology and End Results database 2004-2019. We compared OS between non-seminoma (NS-TGCT) and seminoma (S-TGCT) patients relative to age-matched male population-based controls based on Social Security Administration Life-Tables. Smoothed cumulative incidence plots displayed cancer-specific mortality (CSM) vs. other-cause mortality (OCM).

RESULTS RESULTS

Of all 20,935 TGCT patients, 43% had NS-TGCT and 57% had S-TGCT. Of NS-TGCT patients, 63% were stage I vs. 16% stage II vs. 21% stage III. Of S-TGCT patients, 86% were stage I vs. 8% were stage II vs. 6% stage III. Five-year OS differences between NS-TGCT patients vs age-matched male population-based controls were 97 vs. 99% (Δ = 2%) for stage I, 96 vs. 99% (Δ = 3%) for stage II, 76 vs 98% (Δ = 22%) for stage III. Five-year OS differences between S-TGCT patients vs age-matched male population-based controls were 97 vs. 98% (Δ = 1%) for stage I, 95 vs. 97% (Δ = 2%) for stage II, 87 vs. 98% (Δ = 11%) for stage III. OCM rates ranged from 1 to 3% in NS-TGCT patients and from 2 to 4% in S-TGCT patients.

CONCLUSION CONCLUSIONS

The OS difference between NS-TGCT patients vs. age-matched male population-based controls was invariably higher across all stages (2-22%) than for S-TGCT patients (1-11%). Reassuringly, OCM rates were marginal in stage I and stage II patients. Conversely, higher OCM rates were recorded in stage III patients.

Identifiants

DOI: 10.1007/s11255-023-03763-2 PMID: 37640983

pubmed: 37640983

doi: 10.1007/s11255-023-03763-2

pii: 10.1007/s11255-023-03763-2

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

3119-3128

Informations de copyright

Références

Stephenson A, Eggener SE, Bass EB et al (2019) Diagnosis and treatment of early stage testicular cancer guideline: AUA GUIDELINE

Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol 70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029

doi: 10.1016/j.eururo.2016.02.029 pubmed: 26935559

Cheng L, Albers P, Berney DM et al (2018) Testicular cancer. Nat Rev Dis Primer 4:29. https://doi.org/10.1038/s41572-018-0029-0

doi: 10.1038/s41572-018-0029-0

Chovanec M, Cheng L (2022) Advances in diagnosis and treatment of testicular cancer. BMJ. https://doi.org/10.1136/bmj-2022-070499

doi: 10.1136/bmj-2022-070499 pubmed: 36442868

Gillessen S, Sauvé N, Collette L et al (2021) Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): Results from the IGCCCG Update Consortium. J Clin Oncol 39:1563–1574. https://doi.org/10.1200/JCO.20.03296

doi: 10.1200/JCO.20.03296 pubmed: 33822655 pmcid: 8099402

Beyer J, Collette L, Sauvé N et al (2021) Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. J Clin Oncol 39:1553–1562. https://doi.org/10.1200/JCO.20.03292

doi: 10.1200/JCO.20.03292 pubmed: 33729863 pmcid: 8099394

Park JS, Kim J, Elghiaty A, Ham WS (2018) Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 97:e12390. https://doi.org/10.1097/MD.0000000000012390

doi: 10.1097/MD.0000000000012390 pubmed: 30213007

Social Security Administration-Actuarial Life Table. https://www.ssa.gov/oact/STATS/table4c6.html . Accessed 13 Jan 2023

SEER Cancer Statistics Review, 1975-2018. In: SEER. https://seer.cancer.gov/csr/1975_2018/index.html . Accessed 14 Jan 2023

Preisser F, Bandini M, Mazzone E et al (2019) Validation of the social security administration life tables (2004–2014) in localized prostate cancer patients within the surveillance, epidemiology, and end results database. Eur Urol Focus 5:807–814. https://doi.org/10.1016/j.euf.2018.05.006

doi: 10.1016/j.euf.2018.05.006 pubmed: 29802052

Chierigo F, Borghesi M, Würnschimmel C et al (2022) Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. Int Urol Nephrol 54:1521–1527. https://doi.org/10.1007/s11255-022-03221-5

doi: 10.1007/s11255-022-03221-5 pubmed: 35508792

Würnschimmel C, Nocera L, Wenzel M et al (2022) Race/ethnicity may be an important predictor of life expectancy in localized prostate cancer patients: novel analyses using social security administration life tables. J Racial Ethn Health Disparities. https://doi.org/10.1007/s40615-022-01257-y

doi: 10.1007/s40615-022-01257-y pubmed: 35182370 pmcid: 9988799

Würnschimmel C, Collà Ruvolo C, Nocera L et al (2022) Race/ethnicity determines life expectancy in surgically treated T1aN0M0 renal cell carcinoma patients. Eur Urol Focus 8:191–199. https://doi.org/10.1016/j.euf.2021.02.004

doi: 10.1016/j.euf.2021.02.004 pubmed: 33610487

Cano Garcia C, Piccinelli ML, Tappero S et al (2023) Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities. Int Urol Nephrol 55:1117–1123. https://doi.org/10.1007/s11255-023-03517-0

doi: 10.1007/s11255-023-03517-0 pubmed: 36813873

Garcia CC, Nimer N, Piccinelli ML et al (2023) Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States. Ann Epidemiol. https://doi.org/10.1016/j.annepidem.2023.01.003

doi: 10.1016/j.annepidem.2023.01.003 pubmed: 36473628

R: The R Project for Statistical Computing. https://www.r-project.org/ . Accessed 14 Jan 2023

Palumbo C, Mistretta FA, Mazzone E et al (2019) Contemporary incidence and mortality rates in patients with testicular germ cell tumors. Clin Genitourin Cancer 17:e1026–e1035. https://doi.org/10.1016/j.clgc.2019.06.003

doi: 10.1016/j.clgc.2019.06.003 pubmed: 31378580

Mao W, Wu J, Kong Q et al (2020) Development and validation of prognostic nomogram for germ cell testicular cancer patients. Aging 12:22095–22111. https://doi.org/10.18632/aging.104063

doi: 10.18632/aging.104063 pubmed: 33136554 pmcid: 7695357

Woldu SL, Moore JA, Ci B et al (2018) Practice patterns and impact of postchemotherapy retroperitoneal lymph node dissection on testicular cancer outcomes. Eur Urol Oncol 1:242–251. https://doi.org/10.1016/j.euo.2018.04.005

doi: 10.1016/j.euo.2018.04.005 pubmed: 31058267 pmcid: 6494089

Noureldin YA, Alqirnas MQ, Aljarallah MF et al (2022) Testicular cancer among Saudi adults: hands on a nationwide cancer registry over 10 years. Arab J Urol 20:182–188. https://doi.org/10.1080/2090598X.2022.2084902

doi: 10.1080/2090598X.2022.2084902 pubmed: 36353476 pmcid: 9639499

Yamashita S, Koyama J, Goto T et al (2020) Trends in age and histology of testicular cancer from 1980–2019: a single-center study. Tohoku J Exp Med 252:219–224. https://doi.org/10.1620/tjem.252.219

doi: 10.1620/tjem.252.219 pubmed: 33148936

Facchini G, Rossetti S, Berretta M et al (2019) Prognostic and predictive factors in testicular cancer. Eur Rev Med Pharmacol Sci 23:3885–3891

pubmed: 31115016

Cano Garcia C, Panunzio A, Tappero S et al (2023) Survival of testicular pure embryonal carcinoma vs. mixed germ cell tumor patients across all stages. Medicina (Mex) 59:451. https://doi.org/10.3390/medicina59030451

doi: 10.3390/medicina59030451

Cano Garcia C, Barletta F, Incesu R-B et al (2023) Survival of testicular pure teratoma vs. mixed germ cell tumor patients in primary tumor specimens across all stages. Cancers 15:694. https://doi.org/10.3390/cancers15030694

doi: 10.3390/cancers15030694 pubmed: 36765653 pmcid: 9913474